enGene (ENGN) Competitors $5.83 -0.13 (-2.18%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ENGN vs. VIR, ADPT, PSTX, IMTX, REPL, LENZ, RLAY, AVXL, CGEM, and AUTLShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Vir Biotechnology (VIR), Adaptive Biotechnologies (ADPT), Poseida Therapeutics (PSTX), Immatics (IMTX), Replimune Group (REPL), LENZ Therapeutics (LENZ), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), Cullinan Therapeutics (CGEM), and Autolus Therapeutics (AUTL). These companies are all part of the "biological products, except diagnostic" industry. enGene vs. Vir Biotechnology Adaptive Biotechnologies Poseida Therapeutics Immatics Replimune Group LENZ Therapeutics Relay Therapeutics Anavex Life Sciences Cullinan Therapeutics Autolus Therapeutics enGene (NASDAQ:ENGN) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends. Does the MarketBeat Community prefer ENGN or VIR? Vir Biotechnology received 35 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 53.26% of users gave Vir Biotechnology an outperform vote. CompanyUnderperformOutperformenGeneOutperform Votes14100.00% Underperform VotesNo VotesVir BiotechnologyOutperform Votes4953.26% Underperform Votes4346.74% Do insiders & institutionals have more ownership in ENGN or VIR? 64.2% of enGene shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate ENGN or VIR? enGene presently has a consensus target price of $30.38, suggesting a potential upside of 421.01%. Vir Biotechnology has a consensus target price of $36.40, suggesting a potential upside of 395.91%. Given enGene's stronger consensus rating and higher possible upside, analysts plainly believe enGene is more favorable than Vir Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Vir Biotechnology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is ENGN or VIR more profitable? enGene has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Vir Biotechnology's return on equity of -36.71% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -66.38% -56.00% Vir Biotechnology -678.40%-36.71%-31.00% Which has preferable valuation & earnings, ENGN or VIR? enGene has higher earnings, but lower revenue than Vir Biotechnology. enGene is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$99.92M-$0.58-10.05Vir Biotechnology$62.04M16.29-$615.06M-$3.92-1.87 Does the media favor ENGN or VIR? In the previous week, enGene had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 5 mentions for enGene and 3 mentions for Vir Biotechnology. enGene's average media sentiment score of 1.10 beat Vir Biotechnology's score of 0.05 indicating that enGene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ENGN or VIR? enGene has a beta of -0.78, indicating that its share price is 178% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. SummaryenGene beats Vir Biotechnology on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$263.53M$2.94B$5.02B$9.08BDividend YieldN/A1.90%4.87%4.18%P/E Ratio-10.0546.73135.2017.17Price / SalesN/A411.981,120.31115.67Price / Cash1.66182.1040.5837.88Price / Book1.873.894.754.78Net Income-$99.92M-$42.21M$118.50M$225.60M7 Day Performance-4.11%-2.07%-1.83%-1.26%1 Month Performance-22.27%4.75%12.27%4.37%1 Year Performance-18.23%20.12%31.72%18.73% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene2.9966 of 5 stars$5.83-2.2%$30.38+421.0%-18.2%$263.53MN/A-10.0531Earnings ReportNews CoveragePositive NewsGap UpVIRVir Biotechnology2.0004 of 5 stars$7.56+1.5%$36.40+381.5%-23.6%$1.04B$86.18M-1.90587ADPTAdaptive Biotechnologies2.9495 of 5 stars$6.78+7.6%$6.50-4.1%+34.8%$1.00B$170.28M-4.70709Analyst ForecastNews CoveragePositive NewsPSTXPoseida Therapeutics3.7439 of 5 stars$9.51flat$9.50-0.1%+193.5%$929.79M$64.70M-15.10260Positive NewsIMTXImmatics1.4231 of 5 stars$7.27+0.8%$16.67+129.3%-25.3%$867.72M$115.50M-10.92260REPLReplimune Group4.5404 of 5 stars$12.48-0.6%$17.29+38.5%+67.4%$853.88MN/A-4.15210Insider TradeLENZLENZ Therapeutics0.4915 of 5 stars$30.94-0.1%$35.40+14.4%N/A$850.88MN/A0.00N/ANews CoveragePositive NewsRLAYRelay Therapeutics2.2561 of 5 stars$4.84+2.8%$20.50+323.6%-60.4%$810.12M$25.55M-1.80304Insider TradeAVXLAnavex Life Sciences3.3451 of 5 stars$9.18+8.5%$43.00+368.4%-2.5%$778.46MN/A-18.5440CGEMCullinan Therapeutics1.7981 of 5 stars$11.80+0.4%$31.67+168.4%+32.7%$687.09M$18.94M-4.1430News CoverageAUTLAutolus Therapeutics2.5563 of 5 stars$2.58+3.6%$10.40+303.1%-58.4%$686.51M$1.70M-2.19330 Related Companies and Tools Related Companies VIR Competitors ADPT Competitors PSTX Competitors IMTX Competitors REPL Competitors LENZ Competitors RLAY Competitors AVXL Competitors CGEM Competitors AUTL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENGN Stock Alerts